Allstate Corp Grows Holdings in Xylem Inc. $XYL

Allstate Corp increased its position in Xylem Inc. (NYSE:XYL) by 102.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 17,777 shares of the industrial products company’s stock after acquiring an additional 8,988 shares during the quarter. Allstate Corp’s holdings in Xylem were worth $2,421,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Fisher Asset Management LLC increased its holdings in Xylem by 6.4% in the 3rd quarter. Fisher Asset Management LLC now owns 404,613 shares of the industrial products company’s stock worth $59,681,000 after acquiring an additional 24,352 shares in the last quarter. LGT Capital Partners LTD. increased its stake in Xylem by 18.4% in the 3rd quarter. LGT Capital Partners LTD. now owns 268,704 shares of the industrial products company’s stock worth $39,634,000 after buying an additional 41,730 shares in the last quarter. ABN AMRO Bank N.V. increased its stake in Xylem by 2.3% in the 3rd quarter. ABN AMRO Bank N.V. now owns 1,637,096 shares of the industrial products company’s stock worth $240,511,000 after buying an additional 36,992 shares in the last quarter. Northwestern Mutual Wealth Management Co. increased its stake in Xylem by 2,309.7% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 431,824 shares of the industrial products company’s stock worth $54,314,000 after buying an additional 413,904 shares in the last quarter. Finally, Abacus Wealth Partners LLC purchased a new stake in Xylem in the 4th quarter worth $1,663,000. 87.96% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have issued reports on XYL. Jefferies Financial Group reiterated a “hold” rating and issued a $130.00 price target (down from $140.00) on shares of Xylem in a research note on Tuesday, March 31st. Barclays cut their price target on Xylem from $156.00 to $154.00 and set an “overweight” rating for the company in a research note on Wednesday, April 29th. UBS Group increased their price objective on shares of Xylem from $132.00 to $133.00 and gave the company a “neutral” rating in a report on Wednesday, April 29th. TD Cowen reaffirmed a “hold” rating on shares of Xylem in a report on Monday, February 23rd. Finally, JPMorgan Chase & Co. cut their price objective on shares of Xylem from $170.00 to $160.00 and set an “overweight” rating for the company in a report on Thursday, April 16th. Seven equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat, Xylem currently has a consensus rating of “Moderate Buy” and an average price target of $152.77.

Insiders Place Their Bets

In other Xylem news, Director Jerome A. Peribere bought 1,210 shares of the business’s stock in a transaction that occurred on Monday, May 4th. The stock was purchased at an average cost of $116.61 per share, with a total value of $141,098.10. Following the completion of the acquisition, the director owned 27,209 shares in the company, valued at $3,172,841.49. This trade represents a 4.65% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Geri-Michelle Mcshane sold 4,269 shares of the firm’s stock in a transaction on Thursday, May 7th. The shares were sold at an average price of $117.46, for a total transaction of $501,436.74. Following the completion of the transaction, the chief accounting officer directly owned 3,605 shares of the company’s stock, valued at approximately $423,443.30. This trade represents a 54.22% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 0.32% of the company’s stock.

Xylem Trading Down 1.0%

Shares of Xylem stock opened at $109.00 on Friday. The firm has a market cap of $25.91 billion, a price-to-earnings ratio of 27.11, a PEG ratio of 1.57 and a beta of 1.08. The business has a 50-day moving average price of $118.04 and a 200-day moving average price of $129.90. The company has a quick ratio of 1.10, a current ratio of 1.46 and a debt-to-equity ratio of 0.13. Xylem Inc. has a twelve month low of $105.29 and a twelve month high of $154.27.

Xylem (NYSE:XYL) last issued its quarterly earnings data on Tuesday, April 28th. The industrial products company reported $1.12 earnings per share for the quarter, beating analysts’ consensus estimates of $1.09 by $0.03. The firm had revenue of $2.13 billion during the quarter, compared to analyst estimates of $2.11 billion. Xylem had a return on equity of 11.26% and a net margin of 10.79%.The business’s quarterly revenue was up 2.7% compared to the same quarter last year. During the same quarter last year, the business posted $1.03 earnings per share. Xylem has set its FY 2026 guidance at 5.350-5.600 EPS. Equities research analysts anticipate that Xylem Inc. will post 5.51 EPS for the current fiscal year.

Xylem Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 25th. Investors of record on Thursday, May 28th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Thursday, May 28th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 1.6%. Xylem’s dividend payout ratio (DPR) is 42.79%.

Xylem declared that its board has approved a stock buyback program on Wednesday, February 25th that authorizes the company to repurchase $1.50 billion in shares. This repurchase authorization authorizes the industrial products company to buy up to 4.8% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company’s management believes its stock is undervalued.

Xylem Company Profile

Xylem Inc (NYSE: XYL) is a global water technology company that designs, manufactures and services engineered systems and equipment for the transport, treatment, testing and efficient use of water. Its product portfolio spans pumps and pumping systems, valves, filtration and disinfection equipment, sensors and analytical instruments, and digital solutions for monitoring and control of water infrastructure. Xylem serves the full water cycle with offerings for water and wastewater utilities, industrial customers, commercial and residential buildings, and agricultural applications.

The company was established as an independent publicly traded company in 2011 following a corporate spin-off from ITT Corporation and is headquartered in Rye Brook, New York.